ApoE E4 Immunoassay: A Cost-Effective, Scalable Alternative to DNA Genotyping for Alzheimer’s Disease

APOE ε4 testing is a consequential pre-treatment step in Alzheimer Disease (AD) care. With the approvals of lecanemab and donanemab, knowing a patient's ε4 status is now embedded in drug labeling — not as optional background, but as a clinical requirement that shapes treatment decisions and monitoring protocols. Yet for many practices, particularly those outside academic medical centers, scaling reliable access to that information has both logistical and financial hurdles. An emerging immunoassay-based approach - currently available for research use only - is already demonstrating value in clinical trial screening and biomarker research, and points toward a practical path for broader clinical access.

The Access Gap in APOE Testing

The default route to APOE ε4 status information has been DNA genotyping and for good reason; it is accurate and well-validated. However, it is not universally accessible. Many community neurology practices and health systems lack on-site molecular genotyping infrastructure, making them dependent on external send-out labs. That introduces delays, added costs, and in some cases, practical barriers that can slow or complicate the treatment initiation process. For practices serving rural or underserved populations, these friction points are not trivial — they can meaningfully limit which patients get timely risk assessment and/or access to disease-modifying therapy as these programs scale.

What an ApoE E4 Proteotyping Immunoassay Offers

A fully automated, high-throughput plasma immunoassay for APOE ε4 classification – currently designated research use only (RUO) - offers a practical path to closing this access gap. The Beckman Coulter apoE E4 immunoassay uses a proteotyping approach — quantifying the apoE4 isoform relative to total apoE protein — to classify APOE ε4 zygosity (non-carrier, heterozygote, homozygote) directly from plasma, without requiring DNA analysis. In a peer-reviewed study published in Alzheimer's & Dementia, pooled concordance with PCR genotyping was 99.6% (95% CI 98.4–99.9) across 460 participants from three cohorts — meeting key analytical validity benchmarks for specificity, interference, precision, and stability.¹ In its current form, the assay is already available for research cohort characterization and clinical trial screening, where APOE ε4 status is a key enrollment criterion and the demand for high-throughput, cost-efficient genotyping is high. These workflows mirror those in everyday clinical practice, positioning the assay well for clinical decision-making if it were ultimately to receive regulatory approval.

The practical advantages for clinical laboratories and neurology practices are meaningful:

Workflow compatibility. The assay runs on high-throughput immunoassay platforms already deployed in hospital and reference laboratories, returning results on routine clinical timelines without requiring a separate molecular lab or send-out pathway. Importantly, apoE E4 classification can be performed from the same blood draw used for other plasma biomarkers (e.g., p-tau217) - eventually enabling comprehensive multi-marker AD panels without additional sample collection from the patient.

Cost and scalability. Cost comparisons from non-AD indications suggest PCR-based genotyping costs two to five times more than immunoassay methods - a differential that reflects the dedicated infrastructure, specialized equipment, and trained personnel that molecular approaches require. For health systems aiming to expand AD screening programs or support population-level APOE ε4 assessment, that cost difference compounds quickly at scale.

Broader reach. Eliminating the dependency on molecular genotyping infrastructure lowers barriers in community settings, smaller health systems, and regions where neurology practices routinely rely on external genetics labs. This has real equity implications, both for access to anti-amyloid therapies and for broader risk counseling.

These developments complement rather than replace existing molecular options.The growing ecosystem of testing approaches — immunoassay and molecular — creates more fit-for-purpose routes to APOE ε4 status based on local laboratory capability and patient need.

Bottom Line for Neurologists

APOE ε4 testing is now standard practice for AD risk assessment and a prerequisite ahead of anti-amyloid therapy initiation. The recently published Alzheimer's & Dementia data demonstrated 99.6% concordance between the apoE E4 immunoassay and PCR genotyping is an encouraging development. Currently designated RUO, the assay is not yet available for clinical diagnostic use, but its availability for research cohorts and trial screening means the analytical foundation for clinical translation is already being established.

Still, as disease-modifying treatments move further into everyday neurology practice — including in community settings where most patients receive care — practical, scalable access to APOE ε4 information becomes a prerequisite for equitable care. Tools that bring accurate APOE assessment into routine laboratory workflows, at accessible cost, bring us closer to that goal.

Article submitted by Danaher Diagnostics.

REFERENCES:
1. Levin S, Engel B, Carlson C, et al. An automated plasma-based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease. Alzheimer's Dement. 2026; 22:e71143. https://doi.org/10.1002/alz.71143